Sign up to save your podcasts
Or
Share Oncotarget
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Oncotarget
By Oncotarget PodcastScience
Oncotarget episodes
- Author Insight: Cancer Drug Prices in Low- and Middle-Income CountriesDr. Bishal Gyawali from the Institute of Cancer Policy, London and Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, discusses an editorial he authored that was published by Oncotarget in Volume 8, Issue 52, entitled, “Cancer drugs in LMICs: cheap but unaffordable.”DOI - https://doi.org/10.18632/oncotarget.21976 (PDF download)Full text - https://www.oncotarget.com/article/21976/Correspondence to - Bishal Gyawali - [email protected]; https://twitter.com/oncology_bgSign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.21976Keywords - value, affordability, global oncology, drug prices, cancerAbout OncotargetOncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.comMedia Contact180092209578 min
- Paper Spotlight: Iron Chelators in Cancer TreatmentIron is essential for human life, however, this element can also become toxic in high doses. Contrary to iron anemia, iron overload occurs when the body accumulates more iron than it can use, and this excess iron is damaging to cells and tissues. Famous for their atypical growth patterns, cancer cells accumulate a surplus of iron to support their irregular growth and metabolism. Thus, the metabolism of cancer cells may be exploited by targeting their proclivity to require and retain iron.“Iron chelators selectively deplete cancer cells of iron, exploiting cancer’s iron addiction – a trait displayed by a range of different cancers.”Iron chelators are compounds that can bind to iron and facilitate iron wasting. Depriving the body of iron using iron chelators has selectively cytotoxic effects in cancer cells. Some natural iron chelators include turmeric, quercetin, resveratrol, and green tea. Synthetic iron chelators include derivatives of 8-hydroxyquinoline, tachpyridine and deferoxamine. A considerable number of studies have shown that iron chelators can reverse some major catalysts and hallmarks of cancer—making iron chelators a promising treatment option for cancer patients.Researchers Gina Abdelaal and Stephany Veuger from Northumbria University reviewed the available research literature about the impact of iron chelation on cancer cell survival and the underlying mechanisms of action. Their review paper was published by Oncotarget in 2021 and entitled, “Reversing oncogenic transformation with iron chelation.”Full blog - https://www.oncotarget.org/2022/02/10/iron-chelators-in-cancer-treatment/DOI - https://doi.org/10.18632/oncotarget.27866Correspondence to - Gina Abdelaal - [email protected]Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27866Press release - https://www.oncotarget.com/news/pr/reversing-oncogenic-transformation-with-iron-chelation/Keywords - iron chelator, oncogenesis, selective cytotoxicity, hallmarks of cancer, NDRG1About OncotargetOncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/OncotargetYouTubeLinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.comMedia Contact180092209578 min
- Author Insight: Precision Oncology Improves Patient Survival, Financial BurdensDr. Derrick Haslem and Dr. Lincoln Nadauld from the Precision Genomics Program, Intermountain Healthcare, Saint George, UT, discuss a research paper they co-authored that was published by Oncotarget as the cover for Volume 9, Issue 15, entitled, “Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs.”DOI - https://doi.org/10.18632/oncotarget.24384Correspondence to - Lincoln D. Nadauld - [email protected]AbstractThe impact of precision oncology on guiding treatment decisions of late-stage cancer patients was previously studied in a retrospective analysis. However, the overall survival and costs were not previously evaluated. We report the overall survival and healthcare costs associated with precision oncology in these patients with advanced cancer. Building on a matched cohort study of 44 patients with metastatic cancer who received all of their care within a single institution, we evaluated the overall survival and healthcare costs for each patient. We analyzed the outcomes of 22 patients who received genomic testing and targeted therapy (precision oncology) between July 1, 2013 and January 31, 2015, and compared to 22 historically controlled patients (control) who received standard chemotherapy (N = 17) or best supportive care (N = 5). The median overall survival was 51.7 weeks for the targeted treatment group and 25.8 weeks for the control group (P = 0.008) when matching on age, gender, histological diagnosis and previous treatment lines. Average costs over the entire period were $2,720 per week for the targeted treatment group and $3,453 per week for the control group, (P = 0.036). A separate analysis of 1,814 patients with late-stage cancer diagnoses found that those who received a targeted cancer treatment (N = 93) had 6.9% lower costs in the last 3 months of life compared with those who did not. These findings suggest that precision oncology may improve overall survival for refractory cancer patients while lowering average per-week healthcare costs, resource utilization and end-of-life costs.Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.24384Press release - https://www.oncotarget.com/news/pr/precision-oncology-in-advanced-cancer-patients-improves-overall-survival-with-lower-weekly-healthcare-costs/Keywords - precision medicine, oncology, outcomes, costs, overall survivalAbout OncotargetOncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.comMedia Contact1800922095714 min
- Paper Spotlight: Prognostic Markers Identified in Ultra-Rare Adrenal CancerAdrenocortical carcinoma (ACC) is a rare and aggressive cancer that forms in the outer layer of the adrenal gland tissue above the kidneys. According to the National Institutes of Health, the occurrence of ACC in the United States is believed to only affect one to two people per million, per year. This highly-rare disease also challenges patients and researchers due to its post-diagnosis five-year survival rate of a mere 51%.At this time, there are no known external factors that cause this disease. Most adrenocortical tumors that have been found produce symptoms including abdominal pain and higher levels of certain hormones, inclusive of cortisol, aldosterone, testosterone, and estrogen. Any of these hormones produced in excess can have numerous troubling effects on the body and, most alarmingly, the cancer cells in the adrenal glands have the potential to travel to other organs.Researchers—from the National Cancer Institute, Stanford University, Medical College of Wisconsin, Frederick National Laboratory for Cancer Research, and Salubris Biotherapeutics—conducted a study to learn more about ACC and the mechanisms that lead to the biological materialization of this ultra-rare disease. In 2020, their research paper was published by Oncotarget and entitled, “GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3.”Full blog - https://www.oncotarget.org/2022/01/26/study-demonstrates-excess-of-protein-is-regulated-by-gata3-in-ultra-rare-adrenal-cancer/DOI - https://doi.org/10.18632/oncotarget.27703Correspondence to - Electron Kebebew - [email protected]Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27703Press release - https://www.oncotarget.com/news/pr/gata3-and-apobec3b-are-prognostic-markers-in-adrenocortical-carcinoma-and-apobec3b-is-directly-transcriptionally-regulated-by-gata3/Keywords - adrenocortical carcinoma, APOBEC3B, GATA3, prognosis, DNA damageAbout OncotargetOncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/OncotargetYouTubeLinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.comMedia Contact180092209577 min
- Trending With Impact: What Causes Chemo Brain?A type of mental fog—known as “chemo brain”—is widely experienced by patients who have undergone cancer treatment. Cancer research institutions define chemo brain as impaired cognition, including cloudiness, memory loss and/or lack of concentration, that occurs before, during and/or after cancer treatment. This condition can negatively impact quality of life in a significant way. Chemo brain not only affects recovering individuals but also their loved ones, who often must take on additional caregiving responsibilities. Despite the name, chemotherapeutic drugs may not be the only treatments responsible for chemo brain.A chemotherapy protective drug called amifostine is commonly used in patients and paired with chemotherapeutic agents. Amifostine functions to protect healthy cells from DNA double strand breaks (DSBs) induced by chemotherapy. Another commonly prescribed cancer treatment is called etoposide, which is a chemotherapeutic drug that also targets DSBs. Etoposide, on the other hand, functions to increase DSBs in cancer cells. Recently, researchers have suggested that DSBs could play a role in learning, memory and immediate early gene (IEG) expression. The activity of IEGs can be used to identify neural circuits involved in learning and memory processes.“Despite their wide clinical use, there is little information about how amifostine and etoposide affect learning and memory.”Researchers from Oregon Health and Science University conducted a novel study to observe the isolated effects of these common DSB-altering agents on learning, memory and IEG expression. Systemic injections of amifostine and etoposide were examined in both male and female mice. Their research paper was published by Oncotarget in January of 2022, and entitled, “Common cancer treatments targeting DNA double strand breaks affect long-term memory and relate to immediate early gene expression in a sex-dependent manner.”Full blog - https://www.oncotarget.org/2022/01/28/trending-with-impact-what-causes-chemo-brain/DOI - https://doi.org/10.18632/oncotarget.28180Correspondence to - Jacob Raber - [email protected]Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28180Keywords - amifostine, etoposide, double strand breaks, memory, sexAbout OncotargetOncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with us:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/OncotargetYouTubeLinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.comMedia Contact180092209578 min
- Role of Cancer Associated Fibroblasts in Prostate CancerDr. Nerymar Ortiz-Otero from the Meinig School of Biomedical Engineering, Cornell University, discusses a research paper she co-authored that was published by Oncotarget in Volume 11, Issue 12, entitled, “Cancer associated fibroblasts confer shear resistance to circulating tumor cells during prostate cancer metastatic progression.”DOI - https://doi.org/10.18632/oncotarget.27510Correspondence to - Michael R. King - [email protected]AbstractPrevious studies have demonstrated that CTCs do not travel in the bloodstream alone, but rather are accompanied by clusters of stromal cells such as cancer associated fibroblasts (CAFs). Our laboratory has confirmed the presence of CAFs in the peripheral blood of prostate cancer (PC) patients. The observation that CAFs disseminate with CTCs prompts the examination of the role of CAFs in CTC survival under physiological shear stress during the dissemination process using a clinically relevant, three-dimensional (3D) co-culture model. In this study, we found that “reactive CAFs” induce shear resistance to prostate tumor cells via intercellular contact and soluble derived factors. In addition, these reactive CAFs conserve the proliferative capability of tumor cells in the presence of high magnitude fluid shear stress (FSS). This reactive CAF phenotype emerges from normal fibroblasts (NF), which take on the CAF phenotype when co-cultured with tumor cells. The reactive CAFs showed higher expression of α-smooth muscle actin (α-SMA) and fibroblast activation protein (FAP) compared to differentiated CAFs, when co-cultured with PC cells at the same experimental conditions. Together, we found that the activation mechanism of NF to CAF comprises different stages that progress from a reactive to quiescent cellular state in which these two states are differentiated by the fluctuation of intensity in CAF markers. Here we determined that a reactive state of CAFs proved to be important for supporting tumor cell survival and proliferation. These findings suggest the use of CAFs as a marker for cancer progression and a potential target for novel cancer therapeutics to treat metastatic disease.Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27510Press release - https://www.oncotarget.com/news/pr/cancer-associated-fibroblasts-confer-shear-resistance-to-circulating-tumor-cell/Keywords - metastasis, cancer associated fibroblasts, circulating tumor cells, cytoprotection, collective migrationAbout OncotargetOncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.comMedia Contact180092209578 min
- Oncotarget’s Top-10 Most-Viewed Papers in 2021Listen to a list of the 10 most-viewed oncology-focussed papers on Oncotarget.com in 2021.10 - “Metformin and berberine, two versatile drugs in treatment of common metabolic diseases”DOI - https://doi.org/10.18632/oncotarget.208079 - “Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects”https://doi.org/10.18632/oncotarget.280888 - “Physical activity and telomere length: Impact of aging and potential mechanisms of action”https://doi.org/10.18632/oncotarget.167267 - “Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer”https://doi.org/10.18632/oncotarget.264736 - “cGAS-STING pathway in oncogenesis and cancer therapeutics”https://doi.org/10.18632/oncotarget.276735 - “Anti-aging: senolytics or gerostatics (unconventional view)”https://doi.org/10.18632/oncotarget.280494 - “Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment”https://doi.org/10.18632/oncotarget.277573 - “Scent test using Caenorhabditis elegans to screen for early-stage pancreatic cancer”https://doi.org/10.18632/oncotarget.280352 - “Inflammatory responses and inflammation-associated diseases in organs”https://doi.org/10.18632/oncotarget.232081 - “The goal of geroscience is life extension”https://doi.org/10.18632/oncotarget.27882Keywords - cancer, science, research, oncology, openaccess, researchpapers, journalpublicationAbout OncotargetOncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with us:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetLinkedIn - https://www.linkedin.com/company/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/oncotargetyoutubePinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/OncotargetOncotarget is published by Impact Journals, LLC: https://www.impactjournals.com/Media Contact180092209578 min
- Testimonial: Dr. J. James Frost from Johns Hopkins UniversityDr. J. James Frost, formerly of Johns Hopkins Department of Radiology, talks about his experience publishing the 2017 paper, “Symmetry and symmetry breaking in cancer: a foundational approach to the cancer problem,” with Oncotarget.DOI - https://doi.org/10.18632/oncotarget.22939Correspondence to - J. James Frost - [email protected]Keywords - cancer, symmetry, symmetry-breaking, complexity, scale-freeAbout OncotargetOncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with us:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.comMedia Contact180092209575 min
- Testimonial: Dr. Ken Pienta from Johns Hopkins UniversityDr. Ken Pienta from Johns Hopkins School of Medicine discusses his experiences publishing numerous research papers with Oncotarget.DOI - https://doi.org/10.18632/oncotarget.22939Correspondence to - J. James Frost - [email protected]Keywords - cancer, symmetry, symmetry-breaking, complexity, scale-freeAbout OncotargetOncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with us:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.comMedia Contact180092209571 min
- Testimonial: Dr. Dean Felsher from Stanford UniversityDr. Dean Felsher from Stanford University School of Medicine, Departments of Medicine and Pathology and member of Oncotarget’s Founding Editorial Board, talks about the editorial process at Oncotarget.DOI - https://doi.org/10.18632/oncotarget.22342Correspondence to - Dean W. Felsher - [email protected]Keywords - liver cancer, HCC, miR, MYC, lipid nanoparticle (LNP)About OncotargetOncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with us:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.comMedia Contact180092209571 min
About Oncotarget
From the publisher's feed
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.
Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/